TYRA NASDAQ
Credit Risk of going bust: lower than 76% of companies Debt: 0.5% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.01 (down 99.9%), Tyra Biosciences, Inc. would be worth roughly what it owes.
Total debt $5.6M against a stock market value of $1.22B.
Distance to default 8.81 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $2.8M (short-term plus half of long-term), stock volatility 67.1%; Altman Z'' 11.88. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Carlsbad, CA 92008
US
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Harris Todd | A-Award | 864 | $9.13 | 2026-09-15 |
| Rueb Yuliya | A-Award | 2,925 | $9.13 | 2026-09-15 |
| Fuhrman Alan | A-Award | 951 | $9.13 | 2026-09-15 |
| Verjee Rehan | P-Purchase | 972 | $20.58 | 2026-09-09 |
| Verjee Rehan | A-Award | 13,160 | $32.68 | 2026-05-28 |